Help us determine the optimal timing of an experimental treatment for SOD1 ALS, and whether it can delay clinical onset
Not yet recruiting
Biogen ATLAS Trial
Biogen (sponsor). Academic Lead: Michael Benatar, MD, PhD.
Interventional (double-blind and open-label phases)
Part A (Natural History Run-In)
- Age 18+
- Carrier of a protocol-defined SOD1 mutation
- Clinically pre-symptomatic for ALS
- Plasma neurofilament light (NfL) level below protocol-defined threshold at time of screening
To evaluate whether pre-symptomatic initiation of tofersen can delay the emergence of clinically manifest ALS and/or slow decline in function after emergence of clinically manifest ALS.